How Central Laboratory Services Reduce Costs and Improve Biomarker Data Quality
Biomarker-driven clinical trials are pivotal in drug development, enhancing precision medicine and patient selection while boosting chances of regulatory approval. However, managing these studies can lead to escalating costs due to multiple assays, disjointed logistics, duplicate tests, and risks of sample degradation. Fragmented biomarker analysis across various sites or vendors can result in hidden costs surpassing the explicit costs of the assays.
Central laboratory support streamlines biomarker analysis into a specialized facility, enabling sponsors to reduce costs, prevent redundancy, and safeguard patient samples. CurexBio offers comprehensive central laboratory services that enhance biomarker data quality while keeping expenses low, operating across India, and other nations with a commitment to scientific excellence.
The Costs of Fragmented Biomarker Analysis
Understanding cost-saving methods of central labs begins with identifying the financial losses associated with decentralized models.
- Site-to-Site Variability and Repeats
Variability is inherent in biomarker analysis when conducted at different investigative sites or labs due to differences in equipment, reagents, personnel, and reference ranges. This unpredictability presents a challenge for sponsors, who must decide whether to accept uncertain data or incur extra costs for repeat testing.
The Cost: Repeat testing can significantly increase assay costs and impose additional operational demands, including the need for sample recollection and patient follow-up.
- Logistical Fragmentation
Biomarker samples must be carefully managed with temperature-controlled storage, chain-of-custody documentation, timely processing, and specialized shipping. The logistics involved, spanning various sites and laboratories, introduce significant complexity, with each handoff representing a potential failure and additional costs.
The Cost: Expedited shipping for missed deadlines, replacement samples for compromised specimens, and the management of multiple vendor relationships contribute to administrative overhead.
- Underutilized Capacity
Specialized biomarker assays necessitate costly platforms, such as mass spectrometers and next-generation sequencers, leading to capital and maintenance costs being borne by sponsors when each vendor or site uses its own underutilized equipment.
The Cost: Capital amortization, service contracts, and consumable minimums can be distributed over a significantly larger sample volume.
- Data Management Fragmentation
The integration of biomarker data from various sources requires reconciliation and standardization with clinical databases. Each new source raises query volume, increases cleaning time, and heightens the risk of discrepancies, leading to labor costs for data management that scale nearly linearly with the number of sources.
The Cost: Extended database lock timelines may necessitate additional Full-Time Equivalents (FTEs) for data management, highlighting the concealed risk of submission delays.
- Regulatory Inspection Risk
Decentralized biomarker analysis increases the number of entities under regulatory inspection, requiring each vendor to uphold quality systems and validation documentation. Sponsors need to oversee various quality agreements and audit schedules.
The Cost: Compliance overhead and potential findings can delay submissions, posing a reputational risk due to supplier-related deficiencies.
-
How Central Labs Drive Cost Efficiency
Economies of Scale
A central laboratory efficiently processes numerous samples from various trials, achieving high equipment utilization (80-95% capacity) compared to a decentralized model (10-30% capacity). It benefits from bulk reagent purchasing with volume discounts, employs dedicated specialists, and consolidates quality control, resulting in sponsors paying solely for analyzed data rather than unused resources.
Standardized Logistics
Central labs enhance their logistics infrastructure by employing validated shippers, temperature monitoring, and global courier partnerships, alongside 24/7 sample receiving. This enables sponsors to avoid per-site shipping contract negotiations, ad-hoc courier arrangements, temperature excursion investigations, and sample replacement costs.
Eliminating Redundant Testing
In biomarker analysis, quality control necessitates duplicate testing at site labs, where assays are performed, and sponsors often verify them through re-runs. Central labs streamline this process by conducting all tests in one facility with integrated quality control. For a trial with 500 patients and 10 biomarkers each, decentralized testing involves 5,000 assays plus 500 quality control repeats, while centralized testing only requires the 5,000 assays, resulting in a 10% reduction in total assay volume.
Single Data Management Pipeline
Biomarker data from a central lab is processed through a validated pipeline to the sponsor, streamlining the process by eliminating multiple data transfer agreements, varied file formats, separate query management systems, and fragmented audit trails. This centralized approach can reduce data management efforts for biomarker data by 40-60% compared to multi-vendor models.
Consolidated Regulatory Oversight
One centralized quality system streamlines processes in global regulatory management, leading to significant cost savings. It consolidates vendor qualification to one vendor, simplifies quality agreements to a single negotiation, reduces audit preparation to one audit instead of multiple site visits, and enhances Corrective and Preventive Action (CAPA) management through centralized oversight.
Sample Preservation
The most costly sample is one that needs to be recollected. Central labs utilize validated sample management systems to properly store, track, and preserve specimens for future analysis. This capability allows them to perform additional analysis on archived samples, potentially saving millions in follow-up study costs.
-
The Strategic Value of Central Labs
While cost savings are compelling, central labs deliver value beyond the budget line:
Data Quality and Consistency
Central labs standardize biomarker analysis, reducing variability and producing reliable data that regulators trust through a unified platform, set of reagents, team of analysts, and reference range.
Accelerated Timelines
Optimized workflows enhance the speed of sample processing, data transfer, and query resolution, resulting in quicker database locks and faster submissions.
Assay Continuity Across Studies
For development programs involving multiple trials, a central lab ensures continuity by performing assay validation once, allowing results to be directly comparable across studies, which facilitates meta-analyses and enhances regulatory evidence.
Flexibility for Emerging Biomarkers
As science evolves, new biomarkers are identified, and central labs with extensive technology platforms can rapidly integrate assays without needing to requalify various vendors, a critical advantage in biomarker-focused fields like immuno-oncology and neurology.
Patient-Centric Benefits
Patients experience advantages such as reduced blood draw volumes due to single samples being used for multiple assays, fewer repeat visits necessary for recollections, and confidence in the world-class expertise handling their samples.
At CurexBio, we offer extensive central laboratory services focused on optimizing cost and quality. Our expert team assists sponsors in managing the complexities of biomarker-driven trials effectively. Our biomarker analysis capabilities include flow cytometry for immunophenotyping, immunoassays for soluble biomarkers, molecular diagnostics for gene expression and mutation detection, immunohistochemistry for tissue-based biomarkers, clinical chemistry for safety labs, and specialized assays for custom development.
